Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET.

Gjerløff T, Fedorova T, Knudsen K, Munk OL, Nahimi A, Jacobsen S, Danielsen EH, Terkelsen AJ, Hansen J, Pavese N, Brooks DJ, Borghammer P.

Brain. 2015 Mar;138(Pt 3):653-63. doi: 10.1093/brain/awu369.

Preoperative brain metabolism and quality of life after subthalamic nucleus stimulation in Parkinson's disease.

Langner-Lemercier S, Drapier S, Naudet F, Le Clanche N, Houvenaghel JF, Sauleau P, Jannin P, Haegelen C, Le Jeune F, Vérin M.

J Neurol. 2015;262(4):881-9. doi: 10.1007/s00415-015-7647-1.

Aggressive behavior as a rare side effect of subthalamic stimulation in Parkinson's disease.

Papuć E, Trojanowski T, Obszańska K, Stelmasiak Z.

Neurocase. 2015;21(2):220-5. doi: 10.1080/13554794.2014.890729.

Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease.

Sawada H, Oeda T, Umemura A, Tomita S, Kohsaka M, Park K, Yamamoto K, Sugiyama H.

PLoS One. 2015 Jul 28;10(7):e0134118. doi: 10.1371/journal.pone.0134118.

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease.

Visanji NP, Marras C, Kern DS, Al Dakheel A, Gao A, Liu LW, Lang AE, Hazrati LN.

Neurology. 2015 Feb 10;84(6):609-16.

Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson's Disease Patients.

Wood RA, Hopkins SA, Moodley KK, Chan D.

Front Neurol. 2015 Dec 21;6:263. doi: 10.3389/fneur.2015.00263.

Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.

Lopane G, Mellone S, Chiari L, Cortelli P, Calandra-Buonaura G, Contin M.

Mov Disord. 2015 Aug;30(9):1267-71. doi: 10.1002/mds.26313.

Imagine that: elevated sensory strength of mental imagery in individuals with Parkinson's disease and visual hallucinations.

Shine JM, Keogh R, O'Callaghan C, Muller AJ, Lewis SJ, Pearson J.

Proc Biol Sci. 2015 Jan 7;282(1798):20142047. doi: 10.1098/rspb.2014.2047.

Correction: Neuroanatomical Correlates of Theory of Mind Deficit in Parkinson's Disease: A Multimodal Imaging Study.

PLOS ONE Staff..

PLoS One. 2015 Dec 2;10(12):e0144482. doi: 10.1371/journal.pone.0144482. No abstract available.

Optimising medication for Parkinson's disease patients with dysphagia.

Patel K.

Br J Community Nurs. 2015 Jul;20(7):322, 324-6. doi: 10.12968/bjcn.2015.20.7.322.

Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.

Santiago JA, Potashkin JA.

PLoS One. 2015 Nov 13;10(11):e0142582. doi: 10.1371/journal.pone.0142582.

BEWARE: Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: study protocol for a randomized controlled trial.

Ghielen I, van den Heuvel OA, de Goede CJ, Houniet-de Gier M, Collette EH, Burgers-Bots IA, Rutten S, Kwakkel G, Vermunt K, van Vliet B, Berendse HW, van Wegen EE.

Trials. 2015 Jun 23;16:283. doi: 10.1186/s13063-015-0804-0.

Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.

Sobreira E, Pena-Pereira MA, Eckeli AL, Sobreira-Neto MA, Chagas MH, Foss MP, Cholerton B, Zabetian CP, Mata IF, Tumas V.

Arq Neuropsiquiatr. 2015 Nov;73(11):929-33. doi: 10.1590/0004-282X20150156.

Parkinson disease: Traumatic brain injury increases the risk of Parkinson disease.

Chase A.

Nat Rev Neurol. 2015 Apr;11(4):184. doi: 10.1038/nrneurol.2015.39. No abstract available.

Ginsenoside Rg1 Ameliorates Motor Function in an Animal Model of Parkinson's Disease.

Jiang W, Wang Z, Jiang Y, Lu M, Li X.

Pharmacology. 2015;96(1-2):25-31. doi: 10.1159/000431100.